title: [Reversal effect of matrine on drug resistance of human nasopharyngeal carcinoma cell line].
abstract: OBJECTIVE
  To study the reversal effect of matrine and its derivatives on drug resistance of human nasopharyngeal carcinoma cell line HONE1/DDP.
  
  
  METHODS
  The drug-resistant cell line was established by the human nasopharyngeal carcinoma cells HONE1 with gradually increasing concentration of cisplatin. The matrine and its derivatives were added into the HONE1/DDP according to different concentrations to measure their cytotoxicity. MTT assay was used to measure the reversal effect on the drug resistance of the non-toxic doses of matrine and its derivatives. Cell cycle was measured by flow cytomety. The expression level of MRP1, BAX, BCL-2 was assayed by Western blot.
  
  
  RESULTS
  HONE1/DDP indicated drug resistantance. When the non-toxic doses of matrine and its derivatives were used to HONE1/DDP with 24h, the resistance of HONE1/DDP was down-regulated, the reversal fold was 1.45 and 1.77. The cell number of G0/G1-phase increased in matrine group while S phase decreased in matrine derivatives group compared with HONE1/DDP. Compared with HONE1/DDP group, the MRP1 expression levels in HONE1 cells were reduced (P < 0.05), and Matrine group and matrine derivatives group were enhanced (P < 0.05). The expression of BAX was lower while the expression of BCL-2 was higher.
  
  
  CONCLUSIONS
  The resistance of HONE1 cells to DDP is able to increase the expression of MRP1; Matrine and its derivatives can reverse the drug resistance of HONE1/DDP to DDP, its activity may be related to change cell cycle distribution, the inhibition of MRP1 expression and down-regulation of BAX/BCL-2.
authors.affiliation: Guangxi Medical University, Nanning 530021, China. zhangjun8778@yahoo.com.cn
authors.forename: Jun
authors.initials: J
authors.lastname: Zhang
authors.forename: An-Zhou
authors.initials: AZ
authors.lastname: Tang
mesh_terms: D000470:Alkaloids / Q000737:chemistry / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D002453:Cell Cycle / Q000187:drug effects*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D015394:Molecular Structure; D027425:ATP-Binding Cassette, Sub-Family C Proteins / Q000378:metabolism; D009303:Nasopharyngeal Neoplasms / Q000378:metabolism / Q000473:pathology*; D011807:Quinolizines / Q000737:chemistry / Q000494:pharmacology*; D029909:Sophora / Q000737:chemistry; D051028:bcl-2-Associated X Protein / Q000378:metabolism; D000093842:Matrines
chemical_list: D000470:Alkaloids; D000970:Antineoplastic Agents; D002945:Cisplatin; D027425:ATP-Binding Cassette, Sub-Family C Proteins; D011807:Quinolizines; D051028:bcl-2-Associated X Protein; D000093842:Matrines; C421109:multidrug resistance-associated protein 1